Differential subcellular localization of Ror tyrosine kinase receptors in cultured astrocytes

Glia ◽  
2004 ◽  
Vol 46 (4) ◽  
pp. 456-466 ◽  
Author(s):  
Sabrina Paganoni ◽  
Kelsi L. Anderson ◽  
Adriana Ferreira
Keyword(s):  
Subcellular Localization ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Receptors ◽  
Cultured Astrocytes

Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine

2014 ◽  
Vol 20 (14) ◽  
pp. 2275-2292 ◽  
Author(s):  
Mohamed Altai ◽  
Anna Orlova ◽  
Vladimir Tolmachev
Keyword(s):  
Personalized Medicine ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Receptors

scholarly journals Revising Endosomal Trafficking under Insulin Receptor Activation

2021 ◽  
Vol 22 (13) ◽  
pp. 6978
Author(s):  
Maria J. Iraburu ◽  
Tommy Garner ◽  
Cristina Montiel-Duarte
Keyword(s):  
Plasma Membrane ◽  
Tyrosine Kinase ◽  
Insulin Receptor ◽  
Molecular Mechanisms ◽  
Receptor Activation ◽  
Small Gtpases ◽  
Early Endosome ◽  
Tyrosine Kinase Receptors ◽  
Endosomal Trafficking ◽  
Cell Functions

The endocytosis of ligand-bound receptors and their eventual recycling to the plasma membrane (PM) are processes that have an influence on signalling activity and therefore on many cell functions, including migration and proliferation. Like other tyrosine kinase receptors (TKR), the insulin receptor (INSR) has been shown to be endocytosed by clathrin-dependent and -independent mechanisms. Once at the early endosome (EE), the sorting of the receptor, either to the late endosome (LE) for degradation or back to the PM through slow or fast recycling pathways, will determine the intensity and duration of insulin effects. Both the endocytic and the endosomic pathways are regulated by many proteins, the Arf and Rab families of small GTPases being some of the most relevant. Here, we argue for a specific role for the slow recycling route, whilst we review the main molecular mechanisms involved in INSR endocytosis, sorting and recycling, as well as their possible role in cell functions.

Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma

2014 ◽  
Vol 10 (3) ◽  
pp. 355-363 ◽  
Author(s):  
Jianhong Li ◽  
Cynthia L. Jackson ◽  
Dongfang Yang ◽  
Lelia Noble ◽  
Michael Wheeler ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Urothelial Carcinoma ◽  
Tyrosine Kinase Receptors

A novel tyrosine kinase-independent function of Drosophila abl correlates with proper subcellular localization

Cell ◽  
1990 ◽  
Vol 63 (5) ◽  
pp. 949-960 ◽  
Author(s):  
Mark Henkemeyer ◽  
Steven R. West ◽  
Frank B. Gertler ◽  
F.Michael Hoffmann
Keyword(s):  
Subcellular Localization ◽  
Tyrosine Kinase ◽  
Independent Function

scholarly journals Sunitinib achieved fast and sustained control of VIPoma symptoms

2015 ◽  
Vol 172 (1) ◽  
pp. K1-K3 ◽  
Author(s):  
Louis de Mestier ◽  
Thomas Walter ◽  
Hedia Brixi ◽  
Catherine Lombard-Bohas ◽  
Guillaume Cadiot
Keyword(s):  
Quality Of Life ◽  
Tyrosine Kinase ◽  
Targeted Therapies ◽  
Therapeutic Option ◽  
Somatostatin Analogs ◽  
Watery Diarrhea ◽  
Tyrosine Kinase Receptors ◽  
Secretory Pathways ◽  
Discharge From Hospital

VIPomas are rare-functioning neuroendocrine tumors (NETs). Overproduction of vasointestinal peptide (VIP) leads to the Verner–Morrison syndrome, whose management is challenging when refractory to somatostatin analogs. Two patients with progressive metastatic pancreatic NETs and refractory VIPoma symptoms were treated with sunitinib. This led to fast and sustained total relief of VIPoma symptoms, enabling earlier discharge from hospital and improvement in their quality of life. In both cases, sunitinib discontinuation led to the quick recurrence of watery diarrhea, which resolved within a few days after reintroducing sunitinib. The anti-secretory effect of sunitinib on VIPoma syndrome was probably not related to any anti-tumor effect. These observations agree with the rare reported cases of anti-secretory effects with targeted therapies. The sunitinib-driven inhibition of multiple-tyrosine kinase receptors might act on secretory pathways and describe sunitinib's ability to improve VIPoma symptoms. Sunitinib could be a therapeutic option to control refractory VIPoma symptoms in patients with NETs.

Motor activity affects adult skeletal muscle re-innervation acting via tyrosine kinase receptors

2013 ◽  
Vol 37 (9) ◽  
pp. 1394-1403 ◽  
Author(s):  
Stefano Sartini ◽  
Fanny Bartolini ◽  
Patrizia Ambrogini ◽  
Michele Betti ◽  
Stefano Ciuffoli ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Motor Activity ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Receptors ◽  
Adult Skeletal Muscle
Sign in / Sign up

Export Citation Format

Share Document